Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for AstraZeneca Pharma India's Debt-to-EBITDA or its related term are showing as below:
NSE:ASTRAZEN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.09 Max: 0.39
Current: 0.39
During the past 13 years, the highest Debt-to-EBITDA Ratio of AstraZeneca Pharma India was 0.39. The lowest was 0.02. And the median was 0.09.
NSE:ASTRAZEN's Debt-to-EBITDA is ranked better than 75.18% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs NSE:ASTRAZEN: 0.39
AstraZeneca Pharma India (NSE:ASTRAZEN) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
AstraZeneca Pharma India Debt-to-EBITDA Related Terms
AstraZeneca Pharma India Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ASTRAZEN vs ZTS, UTHR: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Debt-to-EBITDA of 0.42 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on AstraZeneca Pharma India. This is 367% above median its historical median of 0.09. Over the past decade, AstraZeneca Pharma India's Debt-to-EBITDA has ranged from 0.02 to 0.39. According to the industry distribution chart, AstraZeneca Pharma India ranks #171 out of 689 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is AstraZeneca Pharma India's Debt-to-EBITDA too high?
AstraZeneca Pharma India's current Debt-to-EBITDA of 0.42 is 367% above median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.39. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. AstraZeneca Pharma India's value of 0.42 is 75% below this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #171 out of 689 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AstraZeneca Pharma India has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #171 out of 689 companies for Debt-to-EBITDA. This places AstraZeneca Pharma India in the top 25% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.68. AstraZeneca Pharma India's value of 0.42 is 75% below this benchmark. Historically, AstraZeneca Pharma India's own Debt-to-EBITDA has ranged from 0.02 to 0.39 over the past decade. While the company's 10-year median is 0.09 vs. the industry median of 1.68, AstraZeneca Pharma India has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current Debt-to-EBITDA of 0.42 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on AstraZeneca Pharma India. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current Debt-to-EBITDA is 0.42, which is 367% above median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹11,001.94, compared to a current price of ₹7,872.00 — trading 28.4% below its estimated fair value. The current Debt-to-EBITDA is 0.42, which is 367% above median its 10-year median of 0.09 and 75% below the Drug Manufacturers industry median of 1.68. AstraZeneca Pharma India's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Debt-to-EBITDA is 0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹7,872.00 is trading 28.4% below its estimated GF Value™ of ₹11,001.94.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
Debt-to-EBITDA: 0.42 (367% above median its 10-year median of 0.09)
GF Value™: ₹11,001.94 vs. price of ₹7,872.00 (28.4% below fair value)
Industry Position: 75% below the Drug Manufacturers median (#171 of 689)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
93GF Score
Get the complete analysis for NSE:ASTRAZEN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
